• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Let's Get Some Trading Intelligence on Intellia Therapeutics

Can the biotech help the Russell 2000 break out?
By BRUCE KAMICH
Aug 12, 2021 | 12:31 PM EDT
Stocks quotes in this article: NTLA, IWM, AMC

Intellia Therapeutics Inc. (NTLA)  is one of the largest holdings in the iShares Russell 2000 exchange-traded fund  (IWM)  and one Real Money subscriber wonders if this stock can help the IWM break out of its long, sideways trading range. The company is a pioneer in the development of CRISPR/Cas9 genome editing.

 
Let's check it out.
 
In this daily bar chart of NTLA, below, we can see that prices made a six-month base pattern around $75 before the upside price gap in late June. A new high level consolidation has been developing in the past six weeks. Prices are trading above the rising 50-day moving average line and above the rising 200-day line.
 
The trading volume looks like it has been increasing since November as more traders and investors learn about the company and the science. The On-Balance-Volume (OBV) line is strong and helps to confirm the price gains. The Moving Average Convergence Divergence (MACD) oscillator is positive.
 
 
In this weekly Japanese candlestick chart of NTLA, below, we can see some upper shadows above $165, but also some lower shadows around $120. The slope of the 40-week moving average line is positive, but at just half of the price level some would consider NTLA extended or overbought. The OBV line looks strong and supports the price gains so far. The MACD oscillator is in a bullish alignment.
 
 
In this daily Point and Figure chart of NTLA, below, we can see an upside price target in the $199 area.
 
 
Bottom line strategy: In our last review of NTLA on June 29, we wrote that "Too bad I did not review NTLA earlier in June. Prices gapped up on Monday on heavy volume, so I would not anticipate much in the way of price weakness to buy. Traders should go long in the $130 area. Risk to $105 while looking for gains to the $280 area."
 
Traders got a number of opportunities to go long in the $130 area. Continue to hold longs but raise stop protection to your entry price. The $198 area is our first price target with $280 possible longer-term. I don't know if NTLA can excite greater interest in small caps, but it is certainly doing its part. A rally in AMC ( AMC) might help too.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Technical Analysis | Biotechnology

More from Investing

A REIT With Large Total Return Potential and a Generous Current Yield

Paul Price
Jul 4, 2022 9:00 AM EDT

The safe route is to buy shares, collect the generous dividends and reap the rewards when valuations revert back to normal.

Bearish Bets: 3 Stocks You Should Consider Shorting This Week

Bob Lang
Jul 3, 2022 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Let's Shine a Light on Lucid Motors as It Slides Downhill

Brad Ginesin
Jul 2, 2022 1:00 PM EDT

LCID's market cap has been deflated, so is it now a bargain, or can it slip further?

Stop Wishing, Hoping and Praying and Take Control of Your Investing

James "Rev Shark" DePorre
Jul 2, 2022 10:00 AM EDT

The most powerful thing an investor can do is embrace the idea that they don't know what the future holds.

If You've Got Time, These Three Dividend Aristocrats Should Pay Off

Bob Ciura
Jul 2, 2022 7:30 AM EDT

There high-growth dividend stocks will be here over the long haul.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:34 AM EDT PAUL PRICE

    A $525,000 Vote of Confidence on Macerich (MAC)

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • 07:59 PM EDT PAUL PRICE

    Very Good Quarterly Numbers From Bassett Furniture (BSET)

    Bassett Furniture blew right through analysts es...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login